Drug Clinical Trials and Approval Process in India: A Comprehensive Guide

Drug Clinical Trials and Approval in India

Short Description

The approval process for new drugs clinical trials in India can be tricky. The roles of various regulatory authorities are crucial in ensuring high quality and well-researched products reach the consumers. Here’s a step-by-step guide.

Introduction

The drug approval process in India involves getting authorisation from various authorities. This includes stages like application for clinical trials for drugs, conducting trials, applying for marketing authorisation, and conducting post-marketing studies.

Each country has a regulatory authority to enforce rules and issue guidelines to companies seeking to launch their drugs in the market. The approval of new drugs and drug clinical trials in India is a thorough process overseen by several regulatory bodies like the CDSCO, DCGI, etc. This ensures the safety, efficacy, and quality of drugs and clinical trials for drugs.

Regulatory Bodies Overseeing Drug Clinical Trials in India

Understanding the regulatory bodies involved in drug clinical trial services in India is crucial to navigate the approval process. These organisations enforce strict regulations and guidelines to maintain the highest standards of drug safety and efficacy. The main regulatory bodies involved include:

Central Drugs Standard Control Organization (CDSCO): The CDSCO, operating under the Ministry of Health and Family Welfare, is the main regulatory body overseeing the approval of new drugs and drug clinical trials in India. It ensures adherence to national standards.
Drugs Controller General of India (DCGI): The DCGI, an official within the CDSCO, is responsible for approving new drugs and clinical trials. This role is crucial in ensuring the integrity and safety of drug clinical trial services.
Drugs Technical Advisory Board (DTAB): It comprises of special experts who advise the central and state governments on all matters related to drug control enforcement. This board is crucial for central government decision-making, as no rules can be made without consulting the DTAB.
Drugs Consultative Committee: It includes central members and state drug control officers. Its primary role is to ensure uniform application of drug control measures across the country.
Genetic Engineering Approval Committee (GEAC): It oversees the approval process for r-DNA medicinal products and assesses the bio-safety and environmental impact of biotechnological products to ensure safety standards are upheld.
Indian Council of Medical Research (ICMR): It conducts evaluations and provides critical appraisal alongside subject expert committees for conducting clinical trials, as well as for the import, manufacture, and sale of new drugs overseen by the CDSCO.
Institutional Review Boards (IRBs) and Ethics Committees: IRBs and Ethics Committees play a crucial role in reviewing and approving the ethical aspects of clinical trials at local levels. They ensure that the rights and welfare of participants are protected.

Regulatory Body	Role
CDSCO	Oversees drug approval and clinical trials, ensuring national compliance standards are met.
DCGI	Approves new drugs and clinical trials, ensuring the safety and integrity of trials and medications.
DTAB	Advises on drug control enforcement, influencing regulatory policies for effective governance.
Drugs Consultative Committee	Ensures consistent application of drug control measures across India, promoting uniformity in regulations.
GEAC	Approves r-DNA medicinal products and monitors biotechnological product safety to uphold bio-security standards.
ICMR	Provides scientific evaluation and ethical oversight for clinical trials and drug approvals, ensuring research integrity.
IRBs and Ethics Committees	Review and approve ethical aspects of clinical trials, safeguarding participant rights and ensuring ethical conduct in research.

Table 1: Key Regulatory Bodies and Their Roles

Approval Process of Clinical Trials for Drugs

The approval process for drug clinical trials in India can be tedious, time-consuming and expensive. This procedure involves multiple stages of review and evaluation by the afore discussed regulatory bodies. Here’s a brief overview of the steps:

Application Submission: Companies who want to conduct a clinical trial for a drug must submit a detailed application to the CDSCO, including preclinical data and proposed study protocols.
Review and Evaluation: The CDSCO reviews the application, evaluates the scientific validity, and assesses the potential risks and benefits of the clinical trials for drugs.
Ethical Approval: Simultaneously, IRBs and Ethics Committees review the study protocols to ensure ethical standards are met. This step is crucial for protecting participant rights.
Approval and Monitoring: Upon approval, the DCGI grants permission to conduct the clinical trial. Continuous monitoring ensures compliance with regulatory standards throughout the study.

Approval Process of Drug Clinical Trials

Fig 1: Approval Process of Clinical Trials for Drugs

Steps to Ensure Compliance During Regulatory Approval

Ensuring compliance during drug clinical trial services is critical to uphold safety of participants and keep up efficacy standards for new treatments in the healthcare sector. A few key points to keep in mind are:

Good Clinical Practice (GCP): All clinical trials must adhere to GCP guidelines, ensuring ethical and scientific quality standards in the conduct, reporting and design of clinical trials.
Regular Inspections: Regulatory authorities conduct regular inspections of clinical trial sites to ensure compliance with approved protocols and guidelines.
Adverse Event Reporting: Investigators are required to report any adverse events promptly. This allows for timely intervention and ensures participant safety.

Fig 2: Steps to Ensure Compliance During Regulatory Approval

Conclusion

The approval process for drug clinical trials in India is methodically supervised by regulatory bodies ensuring that new medications meet demanding standards of safety. Through systematic review and ethical oversight, the process aims to safeguard participant welfare and uphold public trust in clinical research.

This regulatory framework underscores India’s commitment to advancing drug clinical trial services and facilitating the development of innovative treatments for diverse healthcare needs.

Summary

The drug approval process in India involves multiple difficult stages starting from four phases of clinical trials up to post-marketing studies, overseen by multiple regulatory bodies.
Key regulatory bodies include the CDSCO, DCGI, DTAB, GEAC, ICMR, and IRBs/Ethics Committees, each playing a crucial role in ensuring drug safety and efficacy.
The CDSCO oversees drug approval and clinical trials, maintaining national compliance standards.
The DCGI approves new drugs and clinical trials, ensuring safety and integrity throughout.
IRBs and Ethics Committees safeguard participant rights by reviewing ethical aspects of clinical trials.
Compliance measures like Good Clinical Practice (GCP) and regular inspections uphold safety standards during regulatory approval.

References

1. Gogtay, Nithya J; Ravi, Renju; Thatte, Urmila M. Regulatory requirements for clinical trials in India: What academicians need to know. Indian Journal of Anaesthesia 61(3):p 192-199, March 2017. | DOI: 10.4103/ija.IJA_143_17 Available from: https://journals.lww.com/ijaweb/fulltext/2017/61030/regulatory_requirements_for_clinical_trials_in.2.aspx
2. Gupta, N. Vishal & CR, M & KP, R & Ajay, K & HG, S. (2012). Process of approval of new drug in India with emphasis on clinical trials. International Journal of Pharmaceutical Sciences Review and Research. 13. 17-23. Available from: https://ijprajournal.com/issue_dcp/New%20Drug%20Approval%20Process%20in%20India%20Emphasis%20on%20Clinical%20Trials.pdf
3. Handbook for Applicants and Reviewers of Clinical Trials of New Drugs in India. [Internet] Indian Council of Medical Research [cited 2024 July 1st]. Available from: https://main.icmr.nic.in/sites/default/files/reports/Handbook%20for%20Applicants%20and%20Reviewers%20of%20Clinical%20Trials.pdf
4. Ethics Committee. [Internet] National Institute of Allergy and Infectious Diseases [cited 2024 July 1st]. Available from: https://clinregs.niaid.nih.gov/country/india#ethics_committee
5. Institutional Review Board. [Internet] Oregon State University [cited 2024 July 1st]. Available from: https://research.oregonstate.edu/irb/what-institutional-review-board-irb#:~:text=The%20Institutional%20Review%20Board%20(IRB)%20is%20an%20administrative%20body%20established,with%20which%20it%20is%20affiliated.
6. Draft Guidance on Approval Of Clinical Trials & New Drugs. [Internet] Central Drugs Standard Control Organization [cited 2024 July 1st]. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadAlertsFiles/Guidance_for_New_Drug_Approval-23july2.pdf

Drug

Medical Devices and IVD

Biologicals

Consumer Claims (Cosmetics and Food)

Dermatology and Cosmetic Trials

Clinical Trial Management Services

Project Management

Vendor Management

Site Management

Data management

Medical Writing & Medical Monitoring

Ethics Committee Registration

Clinical Trial Registry India (CTRI)

About Us

Key Opinion Leaders

News and Press Release

Drug Clinical Trials and Approval in India

Related Articles